General Information of Drug (ID: DM0PMKW)

Drug Name
OG-L002 Drug Info
Synonyms
OG-L002; 1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
56639570
TTD Drug ID
DM0PMKW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
IMG-7289 DML9AVG Acute myeloid leukaemia 2A60 Phase 2 [3]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [3]
CC-90011 DM0EDHJ Lymphoma 2A80-2A86 Phase 2 [4]
Vafidemstat DM64ZGY Alzheimer disease 8A20 Phase 2 [5]
ORY-2001 DMYM0UY Alzheimer disease 8A20 Phase 2 [6]
INCB59872 DMRLV7G Acute myeloid leukaemia 2A60 Phase 1/2 [3]
GSK2879552 DMT3V2W Small-cell lung cancer 2C25.Y Phase 1 [7]
Seclidemstat DMCP7SD Ewing sarcoma 2B52 Phase 1 [8]
TAS-1440 DMHIA7Y Acute myeloid leukaemia 2A60 Phase 1 [9]
Tarnylcypromine derivative 2 DMEJR2F N. A. N. A. Patented [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lysine-specific histone demethylase 1 (LSD) TTNR0UQ KDM1A_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7023).
2 A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
5 Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
6 Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
7 A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
8 Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
9 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
10 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.